Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction
- PMID: 29604480
- DOI: 10.1016/j.atherosclerosis.2018.03.027
Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction
Abstract
Background and aims: Nonalcoholic fatty liver disease (NAFLD) may be associated with a wide spectrum of cardiac abnormalities, which share many metabolic risk factors. This study aimed to evaluate whether NAFLD is associated with left ventricular (LV) diastolic dysfunction independent of other classical risk factors.
Methods: A total of 3300 subjects (mean age, 54.1 years; 62.9% men), who underwent echocardiography and hepatic ultrasonography, were enrolled. LV diastolic dysfunction was diagnosed and graded using conventional and Doppler echocardiographic assessments. NAFLD was diagnosed by ultrasonographic findings without any evidence of significant alcohol consumption or viral hepatitis, other liver diseases, or medication provoking fatty liver. Advanced fibrosis was defined as having intermediate-high probability for advanced fibrosis using the NAFLD fibrosis score.
Results: The prevalence of LV diastolic dysfunction was 35.1%. NAFLD had a higher prevalence and severity of LV diastolic dysfunction. The prevalence rates of LV diastolic dysfunction were significantly increased according to the NAFLD fibrosis grade (30.4% for no-NAFLD, 35.2% for NAFLD without advanced fibrosis and 57.4% for NAFLD with advanced fibrosis, p < 0.001). Multivariable analysis showed that NAFLD was associated with a 29% increase in the risk of diastolic dysfunction compared with controls (odds ratio [OR] 1.29; 95% confidence interval [CI] 1.07-1.60). There was significant interaction between obesity (BMI < 25 kg/m2vs. ≥ 25 kg/m2) and advanced fibrosis for LV diastolic dysfunction. A significant, incrementally increased risk of diastolic dysfunction according to the fibrosis grade was more pronounced in the non-obese population [adjusted OR (95% CI), 1.40 (1.06-1.84) for NAFLD without advanced fibrosis, 1.44 (0.95-2.17) for NAFLD with advanced fibrosis vs. no NAFLD, P for trend = 0.022] compared with the obese population (p for trend = 0.081), independent of other well-defined risk factors.
Conclusions: NAFLD was associated with increased risk for LV diastolic dysfunction. In addition, an incrementally increased risk for LV diastolic dysfunction according to fibrosis grade was prominent in the non-obese population.
Keywords: Fibrosis; Heart failure; Hepatic steatosis; Non-obese.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
-
Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus.Diabetes Metab J. 2020 Apr;44(2):267-276. doi: 10.4093/dmj.2019.0001. Epub 2019 Feb 28. Diabetes Metab J. 2020. PMID: 30877708 Free PMC article.
-
Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.J Hepatol. 2018 Apr;68(4):764-772. doi: 10.1016/j.jhep.2017.11.023. Epub 2017 Nov 24. J Hepatol. 2018. PMID: 29175242
-
Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes.PLoS One. 2015 Aug 7;10(8):e0135329. doi: 10.1371/journal.pone.0135329. eCollection 2015. PLoS One. 2015. PMID: 26252899 Free PMC article.
-
Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis.Dig Liver Dis. 2018 Nov;50(11):1166-1175. doi: 10.1016/j.dld.2018.09.004. Epub 2018 Sep 20. Dig Liver Dis. 2018. PMID: 30292566
-
Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis.Hepatol Int. 2022 Apr;16(2):269-281. doi: 10.1007/s12072-022-10319-6. Epub 2022 Mar 23. Hepatol Int. 2022. PMID: 35320497 Review.
Cited by
-
Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan.Int J Mol Sci. 2020 Jun 18;21(12):4337. doi: 10.3390/ijms21124337. Int J Mol Sci. 2020. PMID: 32570776 Free PMC article. Review.
-
Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.Transl Gastroenterol Hepatol. 2020 Jul 5;5:36. doi: 10.21037/tgh.2019.12.02. eCollection 2020. Transl Gastroenterol Hepatol. 2020. PMID: 32632387 Free PMC article. Review.
-
How non-alcoholic fatty liver disease and cirrhosis affect the heart.Hepatol Int. 2023 Dec;17(6):1333-1349. doi: 10.1007/s12072-023-10590-1. Epub 2023 Sep 28. Hepatol Int. 2023. PMID: 37770804 Review.
-
Non-Invasive Serum Markers of Non-Alcoholic Fatty Liver Disease Fibrosis: Potential Tools for Detecting Patients with Cardiovascular Disease.Rev Cardiovasc Med. 2024 Sep 24;25(9):344. doi: 10.31083/j.rcm2509344. eCollection 2024 Sep. Rev Cardiovasc Med. 2024. PMID: 39355605 Free PMC article. Review.
-
Non-alcoholic fatty liver disease and heart failure: A comprehensive bioinformatics and Mendelian randomization analysis.ESC Heart Fail. 2024 Dec;11(6):4185-4200. doi: 10.1002/ehf2.15019. Epub 2024 Aug 14. ESC Heart Fail. 2024. PMID: 39143741 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical